{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 462101108
| IUPAC_name = 
| image = 

<!-- Clinical data -->
| tradename = Increlex
| Drugs.com = {{drugs.com|monograph|mecasermin}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = Rx-only
| legal_status =  
| routes_of_administration = [[Subcutaneous injection|Subcutaneous]]

<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 68562-41-4 
| ATC_prefix = H01
| ATC_suffix = AC03
| PubChem =  
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB01277
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7GR9I2683O
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D04870
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201716
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none

<!-- Chemical data -->
| C=331 | H=512 | N=94 | O=101 | S=7
| molecular_weight = 7648.67 g/mol
| synonyms = FK-780; Recombinant human insulin-like growth factor-1; rhIGF-1; Somatomedin-1
}}

'''Mecasermin''' ([[International Nonproprietary Name|INN]]) (brand name '''Increlex'''), also known as '''recombinant human insulin-like growth factor-1''' ('''rhIGF-1'''), is [[Recombinant DNA|recombinant]] form of human [[insulin-like growth factor 1]] (IGF-I) which is used for the long-term treatment of [[growth failure]] and [[short stature]] in children with severe primary IGF-I deficiency, for instance due to [[growth hormone deficiency]] or [[Laron syndrome]] ([[growth hormone]] insensitivity).<ref>{{cite journal|pmid=19707272|year=2009|last1=Fintini|first1=D|last2=Brufani|first2=C|last3=Cappa|first3=M|title=Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency|volume=5|issue=3|pages=553â€“9|pmc=2724186|journal=Therapeutics and clinical risk management|doi=10.2147/tcrm.s6178}}</ref><ref>{{cite web|url=http://www.drugs.com/increlex.html|title=Increlex|publisher=Drugs.com|accessdate=10 January 2010}}</ref>

A related drug is [[mecasermin rinfabate]] (trade name Iplex), which is a combination of rhIGF-1 and insulin-like growth factor binding protein-3 ([[IGFBP-3]]). IGFBP-3 serves to prolong the action of IGF-1 in the human body.

==References==
{{Reflist|2}}


{{Growth factor receptor modulators}}
{{Signaling peptide/protein receptor modulators}}

[[Category:Endocrinology]]
[[Category:Growth hormones]]
[[Category:Peptides]]


{{systemic-hormonal-drug-stub}}